Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Change in Accured Expenses (2016 - 2025)

Sunshine Biopharma's Change in Accured Expenses history spans 12 years, with the latest figure at -$565040.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 132.2% year-over-year to -$565040.0; the TTM value through Dec 2025 reached -$189956.0, down 104.77%, while the annual FY2025 figure was -$189956.0, 104.77% down from the prior year.
  • Change in Accured Expenses reached -$565040.0 in Q4 2025 per SBFM's latest filing, down from $1.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.8 million in Q4 2024 to a low of -$1.0 million in Q2 2023.
  • Average Change in Accured Expenses over 5 years is $124379.8, with a median of -$46044.0 recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: soared 6943.87% in 2021, then crashed 10997.79% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at -$4378.0 in 2021, then plummeted by 2413.23% to -$110029.0 in 2022, then crashed by 605.41% to -$776161.0 in 2023, then skyrocketed by 326.07% to $1.8 million in 2024, then plummeted by 132.2% to -$565040.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Change in Accured Expenses are -$565040.0 (Q4 2025), $1.2 million (Q3 2025), and -$363693.0 (Q2 2025).